Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Research & Development

Contact Us

Sanofi

Sanofi House,
CTS No.117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400072

Tel no. (022) 28032000
Fax no.(022) 28032846

Content :

Pipeline

After a complete review in of our R&D portfolio in early 2009, Sanofi has 51 projects in clinical development, of which 14% are biotechnology products and 35% vaccines.

 

Among the various projects which recently entered Phase III, there are:

  • the IMOJEV™ vaccine (Japanese encephalitis)
  • the micro-injection influenza vaccine

Among the applications for approval, the application of Ciltyri® (eplivanserin), in the treatment of sleep disorders, was submitted to the FDA and the EMEA during the fourth quarter of 2008 and accepted for filing.

The dossier on Multaq® has been submitted for regulatory approval in Europe and the United States in 2008 and given a priority review.

Updated March 19, 2010

Module :

Corporate information

Corporate information